Data demonstrate sustained peritoneal disease control and reinforce the potential of Oncoinvent's novel radiopharmaceutical therapy to target peritoneal disease in colorectal cancer OSLO, Norway, June 18, 2025 /PRNewswire/ -- Oncoinvent ASA, a clinical-stage radiopharmaceutical company...
Read More Details
Finally We wish PressBee provided you with enough information of ( Oncoinvent Announces Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases )
Also on site :
- 'Days of Our Lives' Icon, 74, Makes Bold Confession About Character
- Israel Says It Killed a Top Iranian Military Leader as Trump Calls for Iran’s Surrender
- Fyodor Lukyanov: Here’s how the West made Israel-Iran war possible